Home > Insider Trading > Filing (0001209191-13-023315)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
816284	Celgene Corp	CELG	Pharmaceutical Preparations (2834)	222711928

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1190435	D Michael Casey	C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-04-29	5,706	$11.21	5,706	No	4	M	Direct
Common Stock	Disposition	2013-04-29	5,706	$0.00	0	No	5	G	Direct
Common Stock	Disposition	2013-04-29	5,706	$120.11	19,458	No	4	S	Indirect	By family trust
Common Stock	Acquisiton	2013-04-30	9,294	$11.21	9,294	No	4	M	Direct
Common Stock	Disposition	2013-04-30	9,294	$0.00	0	No	5	G	Direct
Common Stock	Disposition	2013-04-30	9,294	$118.07	19,458	No	4	S	Indirect	By family trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	5	G	Direct
No	4	S	Indirect	By family trust
No	4	M	Direct
No	5	G	Direct
No	4	S	Indirect	By family trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2013-04-29	5,706	$0.00	5,706	$11.21
Common Stock	Stock Option (right to buy)	Disposition	2013-04-30	9,294	$0.00	9,294	$11.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,294		2013-12-15	No	4	M	Direct
0		2013-12-15	No	4	M	Direct

Footnotes

Represents transfer of shares to the reporting person's family trust. The reporting person is a trustee of the trust and the beneficiaries of the trust are members of the reporting person's immediate family.
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person's family trust in multiple transactions at prices ranging from $120.00 to $120.3550, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person's family trust in multiple transactions at prices ranging from $118.00 to 118.26, inclusive.
Option is fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.